Proteomic analysis identified N-cadherin, clusterin, and HSP27 as mediators of SPARC (secreted protein, acidic and rich in cysteines) activity in melanoma cells

Proteomics

Volumn 7, Issue 22, 2007, Pages 4123-4134

  Sosa, María Soledad ^a,d   Girotti, María Romina ^a   Salvatierra, Edgardo ^a   Prada, Federico ^a   De Olmo, Juan Antonio López ^b,e   Gallango, Silvia Juárez ^b   Albar, Juan Pablo ^b   Podhajcer, Osvaldo Luis ^a   Llera, Andrea Sabina ^a,c  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^c FUNDACIÓN INSTITUTO LELOIR   (Argentina)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

Author keywords

Melanoma; Osteonectin; Secreted protein; SPARC; Two dimensional gel electrophoresis

Indexed keywords

CLUSTERIN; COMPLEMENTARY RNA; CYSTEINE; HEAT SHOCK PROTEIN 27; NERVE CELL ADHESION MOLECULE; OSTEONECTIN; PROTEIN SPARC; UNCLASSIFIED DRUG;

ARTICLE; CELL GROWTH; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS;

CADHERINS; CELL LINE, TUMOR; CLUSTERIN; HEAT-SHOCK PROTEINS; HUMANS; MELANOMA; NEOPLASM PROTEINS; OSTEONECTIN; PROTEOMICS; TUMOR CELLS, CULTURED;

EID: 36549055112     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.200700255     Document Type: Article

References (63)

1. Brekken, R. A., Sage, E. H., SPARC, a matricellular protein: At the crossroads of cell-matrix communication. Matrix Biol. 2000, 19, 569-580.
2. Bradshaw, A. D., Sage, E. H., SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J. Clin. Invest. 2001, 107, 1049-1054.
3. 2+-binding glycoprotein SPARC modulates cell cycle progression in bovine aortic endothelial cells. Proc. Natl. Acad. Sci USA 1991, 88, 2648-2652.
4. Funk, S. E., Sage, E. H., Differential effects of SPARC and cationic SPARC peptides on DNA synthesis by endothelial cells and fibroblasts. J. Cell Physiol. 1993, 154, 53-63.
5. Kupprion, C., Motamed, K., Sage, E. H., SPARC (BM-40, Osteonectin) inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells. J. Biol. Chem. 1998, 273, 29635-29640.
6. 2+-dependent binding to the extracellular matrix. J. Cell. Biol. 1989, 109, 341-356.
7. Barker, T. H., Baneyx, G., Cardo-Vila, M., Workman, G. A., et al., SPARC regulates extracellular matrix organization through its modulation of integrin-linked kinase activity. J. Biol. Chem. 2005, 280, 36483-36493.
8. Yan, Q., Sage, E. H., SPARC, a matricellular glycoprotein with important biological functions. J. Histochem. Cytochem. 1999, 47, 1495-1506.
9. Ledda, M. F., Bravo, A. I., Adris, S., Bover, L. et al., The expression on the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. J. Invest. Dermatol. 1997, 108, 210-214.
10. Rempel, S. A., Ge, S., Gutiérrez, J. A., SPARC: A potential diagnostic marker of invasive meningiomas. Clin. Cancer Res. 1999, 5, 237-241.
11. Bos, T. J., Cohn, S. L., Kleinman, H. K., Murphy-Ulrich, J. E. et al., International Hermelin brain tumor symposium on matricellular proteins in normal and cancer cell-matrix interactions. Matrix Biol. 2004, 23, 63-69.
12. Sato, N., Fukushima, N., Maehara, N., Matsubayashi, H. et al., SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene 2003, 22, 5021-5030.
13. Ledda, M. F., Adris, S., Bravo, A. I., Kairiyama, C. et al., Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat. Med. 1997, 3, 171-175.
14. Woelfle, U., Cloos, J., Sauter, G., Riethdorf, L. et al., Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res. 2003, 63, 5679-5684.
15. Campo McKnight, D. A., Sosnoski, D. M., Koblinski, J. E., Gay, C. V., Roles of osteonectin in the migration of breast cancer cells into bone. J. Cell Biochem. 2005, 97, 288-302.
16. Mok, S. C., Chan, W. Y., Wong, K. K., Muto, M. G., Berkowitz, R. S., SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells. Oncogene 1996, 12, 1895-1901.
17. Yiu, G. K., Chan, W. Y., Ng, S. W., Chan, P. S. et al., SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am. J. Pathol. 2001, 159, 609-622.
18. Chlenski, A., Liu, S., Crawford, S. E., Volpert, O. V. et al., SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis. Cancer Res. 2002, 62, 7357-7363.
19. Alvarez, M. J., Prada, F., Salvatierra, E., Bravo, A. I. et al., Secreted protein acidic and rich in cysteine produced by human melanoma cells modulates polymorphonuclear leukocyte recruitment and antitumor cytotoxic capacity. Cancer Res. 2005, 65, 5123-5132.
20. Kairiyama, C., Slavutsky, I., Larripa, I., Morvillo, V. et al., Biologic, immunocytochemical, and cytogenetic characterization of two new human melanoma cell lines: IIB-MEL-LES and IIB-MEL-IAN. Pigment Cell Res. 1995, 8, 121-131.
21. Gorg, A., Obermaier, C., Boguth, G., Harder, A. et al., The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis 2000, 21, 1037-1053.
22. Heukeshoven, J., Dernick, R., Improved silver staining procedure for fast staining in phastSystem development unit. I. staining of sodium dodecyl sulfate gels. Electrophoresis 1988, 9, 28-32.
23. Shevchenko, A., Wilm, M., Vorm, O., Mann, M., Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal. Chem. 1996, 68, 850-858.
24. Reed, L. J., Muench, H., A simple method of estimating fifty per cent endpoints. Am. J. Hyg. 1938, 27, 493-497.
25. Chomczynski, P., Sacchi, N., Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 1987, 162, 156-159.
26. Bradshaw, A. D., Reed, M. J., Sage, E. H., SPARC-null mice exhibit accelerated cutaneous wound closure. J. Histochem. Cytochem. 2002, 50, 1-10.
27. Bradshaw, A. D., Puolakkainen, P., Dasgupta, J., Davidson, J. M. et al., SPARC-null mice display abnormalities in the dermis characterized by decreased collagen fibril diameter and reduced tensile strength. J. Invest Dermatol. 2003, 120, 949-955.
28. Reiss, K., Maretzky, T., Ludwig, A., Tousseyn, T. et al., ADAM10 cleavage of N-cadherin and regulation of cell-cell adhesion and beta-catenin nuclear signalling. EMBO J. 2005, 24, 742-752.
29. Utton, M. A., Eickholt, B., Howell, F. V., Wallis, J., Doherty, P., Soluble N-cadherin stimulates fibroblast growth factor receptor dependent neurite outgrowth and N-cadherin and the fibroblast growth factor receptor co-cluster in cells. J. Neurochem. 2001, 76, 1421-1430.
30. Paradies, N. E., Grunwald, G. B., Purification and characterization of NCAD90, a soluble endogenous form of N-cadherin, which is generated by proteolysis during retinal development and retains adhesive and neurite-promoting function. J. Neurosci. Res. 1993, 36, 33-45.
31. Prada, F., Benedetti, L. G., Bravo, A. I., Alvarez, M. J. et al., SPARC endogenous level, rather than fibroblast-produced SPARC or stroma reorganization induced by SPARC, is responsible for melanoma cell growth. J. Invest. Dermatol. 2007, DOI:10.1038/sj.jid.5700962, in press.
32. Haass, N. K., Smalley, K. S., Li, L., Herlyn, M., Adhesion, migration and communication in melanocytes and melanoma. Pigment Cell Res. 2005, 18, 150-159.
33. Kuphal, S., Bosserhoff, A. K., Influence of the cytoplasmic domain of E-cadherin on endogenous N-cadherin expression in malignant melanoma. Oncogene 2006, 25, 248-259.
34. Silye, R., Karayiannakis, A. J., Syrigos, K. N., Poole, S. et al., E-cadherin/catenin complex in benign and malignant melanocyte lesions. J. Pathol. 1998, 186, 350-355.
35. Li, G., Satyamoorthy, K., Herlyn, M., Dynamics of cell interactions and communications during melanoma development. Crit. Rev. Oral Biol. Med. 2002, 13, 62-70.
36. Robert, G., Gaggioli, C., Bailet, O., Chavey, C. et al., SPARC Represses E-Cadherin and Induces Mesenchymal Transition during Melanoma Development. Cancer Res. 2006, 66, 7516-7523.
37. Alonso, S. R., Tracey, L., Ortiz, P., Perez-Gomez, B. et al., A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. Cancer Res. 2007, 67, 3450-3460.
38. O'Sullivan, J., Whyte, L., Drake, J., Tenniswood, M., Alterations in the post-translational modification and intracellular trafficking of clusterin in MCF-7 cells during apoptosis. Cell Death Differ. 2003, 10, 914-927.
39. Leskov, K. S., Klokov, D. Y., Li, J., Kinsella, T. J., Boothman, D. A., Synthesis and functional analyses of nuclear clusterin, a cell death protein. J. Biol. Chem. 2003, 278, 11590-11600.
40. Pucci, S., Bonanno, E., Pichiorri, F., Angeloni, C., Spagnoli, L. G., Modulation of different clusterin isoforms in human colon tumorigenesis. Oncogene 2004, 23, 2298-2304.
41. Miyake, H., Hara, I., Kamidono, S., Gleave, M. E., Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Clin. Cancer Res. 2001, 7, 4245-4252.
42. Hoeller, C., Pratscher, B., Thallinger, C., Winter, D. et al., Clusterin regulates drug-resistance in melanoma cells. J. Invest Dermatol. 2005, 124, 1300-1307.
43. Tai, I. T., Dai, M., Owen, D. A., Chen, L. B., Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. J. Clin. Invest. 2005, 115, 1492-1502.
44. Shi, Q., Bao, S., Maxwell, J. A., Reese, E. D. et al., Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation. J. Biol. Chem. 2004, 279, 52200-52209.
45. Volmer, M. W., Radacz, Y., Hahn, S. A., Klein-Scory, S. et al., Tumor suppressor Smad4 mediates downregulation of the anti-adhesive invasion-promoting matricellular protein SPARC: Landscaping activity of Smad4 as revealed by a "secretome" analysis. Proteomics 2004, 4, 1324-1334.
46. Volmer, M. W., Stuhler, K., Zapatka, M., Schoneck, A. et al., Differential proteome analysis of conditioned media to detect Smad4 regulated secreted biomarkers in colon cancer. Proteomics 2005, 5, 2587-2601.
47. Wegrowski, Y., Perreau, C., Martiny, L., Haye, B. et al., Transforming growth factor beta-1 up-regulates clusterin synthesis in thyroid epithelial cells. Exp. Cell Res. 1999, 247, 475-483.
48. Jin, G., Howe, P. H., Transforming growth factor beta regulates clusterin gene expression via modulation of transcription factor c-Fos. Eur. J. Biochem. 1999, 263, 534-542.
49. Reed, M. J., Vernon, R. B., Abrass, I. B., Sage, E. H., TGF-b 1 induces the expression of type I collagen and SPARC, and enhances contraction of collagen gels, by fibroblasts from young and aged donors. J. Cell Physiol. 1994, 158, 169-179.
50. Ford, R., Wang, G., Jannati, P., Adler, D. et al., Modulation of SPARC expression during butyrate-induced terminal differentiation of cultured human keratinocytes: regulation via a TGF-beta-dependent pathway. Exp. Cell Res. 1993, 206, 261-275.
51. Bassuk, J. A., Pichler, R., Rothmier, J. D., Pippen, J. et al., Induction of TGF-beta1 by the matricellular protein SPARC in a rat model of glomerulonephritis. Kidney Int. 2000, 57, 117-128.
52. Eustace, B. K., Sakurai, T., Stewart, J. K., Yimlamai, D. et al., Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat. Cell Biol. 2004, 6, 507-514.
53. Celis, J. E., Gromov, P., Cabezon, T., Moreira, J. M. et al., Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery. Mol. Cell. Proteomics 2004, 3, 327-344.
54. Garrido, C., Schmitt, E., Cande, C., Vahsen, N. et al., HSP27 and HSP70: potentially oncogenic apoptosis inhibitors. Cell Cycle 2003, 2, 579-584.
55. Garrido, C., Fromentin, A., Bonnotte, B., Favre, N. et al., Heat shock protein 27 enhances the tumorigenicity of immunogenic rat colon carcinoma cell clones. Cancer Res. 1998, 58, 5495-5499.
56. Lemieux, P., Oesterreich, S., Lawrence, J. A., Steeg, P. S. et al., The small heat shock protein hsp27 increases invasiveness but decreases motility of breast cancer cells. Invasion Metastasis 1997, 17, 113-123.
57. Aldrian, S., Trautinger, F., Frohlich, I., Berger, W. et al., Overexpression of Hsp27 affects the metastatic phenotype of human melanoma cells in vitro. Cell Stress Chaperones 2002, 7, 177-185.
58. Aldrian, S., Kindas-Mugge, I., Trautinger, F., Frohlich, I. et al., Overexpression of Hsp27 in a human melanoma cell line: regulation of E-cadherin, MUC18/MCAM, and plasminogen activator (PA) system. Cell Stress Chaperones 2003, 8, 249-257.
59. Gronborg, M., Kristiansen, T. Z., Iwahori, A., Chang, R. et al., Biomarker discovery from pancreatic cancer secretome using a differential proteomics approach. Mol. Cell. Proteomics 2006, 5, 157-171.
60. Lafon-Cazal, M., Adjali, O., Galeotti, N., Poncet, J. et al., Proteomic analysis of astrocytic secretion in the mouse: Comparison with the cerebrospinal fluid proteome. J. Biol. Chem. 2003, 278, 24438-24448.
61. Fevrier, B., Raposo, G., Exosomes: endosomal-derived vesicles shipping extracellular messages. Curr. Opin. Cell. Biol. 2004, 16, 415-421.
62. Clayton, A., Turkes, A., Navabi, H., Mason, M. D., Tabi, Z., Induction of heat shock proteins in B-cell exosomes. J. Cell Sci. 2005, 118, 3631-3638.
63. Thery, C., Zitvogel, L., Amigorena, S., Exosomes: composition, biogenesis and function. Nat. Rev. Immunol. 2002, 2, 569-579.